NCT03384238 2026-03-17
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT05901545 2026-03-05
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT03510208 2026-02-09
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
NCT05747625 2025-12-19
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Vanderbilt-Ingram Cancer Center
Phase 1 Recruiting
NCT06714357 2025-12-17
VICTORIA
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT06978400 2025-05-18
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
Phase 2 Recruiting
NCT06575127 2024-08-28
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Al-Azhar University
Phase 2 Recruiting
NCT06509126 2024-07-19
IMPROVE-2
National Cancer Institute, Naples
Phase 3 Recruiting
NCT06314997 2024-03-18
Liquid-DRER2
Matteo's Friends
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting